Careers Media center Contacts

Arterium Corporation* launches new neurological medicinal product

Arterium Corporation* launches new neurological medicinal product

19 October 2016 | News

      Arterium Corporation has launched a new product in the Ukrainian market—Mediatorn, a neurological drug. Mediatorn's active agent ipidacrine hydrochloride stimulates propagation of nerve impulses in the central and peripheral nervous system.
      The drug is desirable in neurological practice, where it can help treat peripheral nervous system inflammations, polyneuropathies, polyradiculopathies, myasthenia and myasthenic syndrome, bulbar paralysis, and multiple sclerosis. The product is also prescribed during the recovery from organic damage to the central nervous system resulting in motor defects.
      Arterium Corporation's Mediatorn is a generic drug that is more affordable than import analogues in the similar dosage. Its quality is on par with the foreign counterparts, which makes it a more cost-effective solution to the problem. The drug is produced by Galychpharm, a part of Arterium Corporation, from the substances sourced from Spain and in full compliance with good manufacturing practices. It is offered in the form of a solution for injections (10 vials in a package, 1 ml each).

*Arterium Corporation includes Arterium Corporation itself and its parts Kievmedpreparat and Galychpharm.
The information is provided for medical and pharmaceutical personnel only and shall be used only in relevant professional activities. The information given here is abridged. For full information about the medicinal product, refer to its instruction for medical use.
This website is a specialised publication intended for medical and pharmaceutical personnel only.

Media gallery
PRESS KIT

Here you can find general information about the company intended for journalists and other stakeholders

MEDIA CONTACTS

For all media-related enquiries,
please contact us
e-mail: pr@arterium.ua
mob.: +38093 124 87 26